You are an elite MBBS pharmacology professor, clinical pharmacologist, physiologist, medical educator, and examination coach. Create a COMPLETE LEARNING NOTE on pharmacokinetics. The goal is not to summarize the topic. The goal is to teach it so thoroughly that an MBBS student never needs another resource to understand the concepts. Assume the student is learning Pharmacokinetics for the very first time. Write in very clear, plain English. Begin every concept at a level understandable by a 9-year-old before gradually building to MBBS-level depth. Never use unexplained terminology. Whenever a scientific term is introduced: First define it. Then explain why it exists. Then explain why it matters clinically. Then explain it using an everyday analogy. Finally explain it again using correct medical language. For every concept, use the following structure. SECTION 1: THE BIG PICTURE Begin by answering: What is Pharmacokinetics? Why do doctors need to understand it? Why do pharmacists need to understand it? How does it affect every drug used in medicine? Explain that Pharmacokinetics answers one major question: "What does the body do to the drug?" Introduce the ADME framework naturally before discussing each component. SECTION 2: BUILD THE FOUNDATION Before discussing any concept, explain the necessary physiology. Teach: Cell membranes Body fluid compartments Blood circulation Organ blood flow The liver The kidneys The gastrointestinal tract Protein binding Explain how these normal body systems determine what happens to drugs. SECTION 3: TEACH EACH CONCEPT STEP BY STEP Cover every pharmacokinetic principle individually. Examples include: Drug absorption, Factors affecting drug absorption Routes of administration Bioavailability First-pass metabolism Drug distribution Volume of distribution Protein binding Drug metabolism Phase I reactions Phase II reactions Cytochrome P450 enzymes Enzyme induction Enzyme inhibition Drug excretion Renal clearance Hepatic clearance Half-life Steady-state concentration Loading dose Maintenance dose Clearance For every topic explain: Definition Purpose Underlying physiology Mechanism Clinical importance Factors affecting it Examples Common mistakes students make Clinical implications High-yield examination points SECTION 4: BUILD MENTAL PICTURES Use vivid analogies. Examples: The bloodstream as a highway. The liver as a chemical factory. The kidney as a water filtration plant. Plasma proteins as buses carrying passengers. Cell membranes as security gates. Volume of distribution as guests spreading throughout a hotel. Always explain the analogy before returning to scientific language. SECTION 5: STEP-BY-STEP CLINICAL THINKING Demonstrate how pharmacokinetics affects patient care. Examples: Why intravenous drugs act faster. Why oral drugs may fail. Why liver disease changes dosing. Why kidney disease causes toxicity. Why elderly patients need dose adjustment. Why obesity changes drug distribution. Walk through each clinical scenario logically. SECTION 6: CONNECT ALL THE CONCEPTS Constantly connect one concept to another. For example: Absorption affects bioavailability. Bioavailability affects plasma concentration. Plasma concentration affects distribution. Distribution affects metabolism. Metabolism affects elimination. Elimination affects half-life. Half-life affects dosing interval. Show how pharmacokinetics is one continuous process rather than isolated topics. SECTION 7: VISUAL LEARNING Create: Flowcharts Comparison tables Simple text illustrations Concept maps Make every difficult topic visual. SECTION 8: MEMORY TOOLS Create: Simple mnemonics Memory stories Visual memory tricks Comparison charts Rapid review tables Avoid forced mnemonics. SECTION 9: EXAMINER'S CORNER Include: Most tested concepts Most repeated essay questions Most repeated short notes Most repeated viva questions Most repeated MCQs Common examination traps Common misconceptions SECTION 11: HIGH-YIELD REVISION SHEET End with: One-page rapid review Most important definitions Most important formulas Most important graphs Most tested concepts Clinical pearls Exam emergency facts SECTION 12: SELF-ASSESSMENT Generate: 20 SBA/MCQs/Viva questions 10 SAQs/Clinical case questions Provide detailed explanations for every answer. SPECIAL INSTRUCTIONS Teach before summarizing. Never assume prior knowledge. Explain every concept from first principles. Build understanding instead of memorization. Constantly connect concepts together. Use simple English while maintaining MBBS accuracy. Make this note comprehensive enough to replace a standard pharmacology textbook for conceptual understanding.

Reading File

Finding Sources

Now let me read the core pharmacokinetics sections from Katzung and Goodman & Gilman in parallel:

Reading File

Finding Sources

Reading File

I now have rich content from Goodman & Gilman, Katzung, and Lippincott. Let me read the distribution, metabolism, and elimination sections:

Reading File

I now have comprehensive content from all three major pharmacology textbooks. Let me write the complete learning note:

PHARMACOKINETICS: THE COMPLETE LEARNING NOTE

A Total Learning Resource for MBBS Students - Built from Goodman & Gilman, Katzung, and Lippincott

SECTION 1: THE BIG PICTURE

What Is Pharmacokinetics? (Start Here - Age 9 Level)

Imagine you swallow a pill. That pill travels into your stomach, gets broken apart, moves into your blood, travels to your heart, lungs, liver, and eventually reaches the part of your body that needs it - maybe your sore throat, or your infected kidney. Then, slowly, your body gets rid of it.

Every single step of that journey - from the moment you swallow the pill to the moment the last molecule leaves your body - is called pharmacokinetics.

The simplest definition: Pharmacokinetics is the study of what the body does to a drug.

(Contrast this with pharmacodynamics, which is what the drug does to the body. You will study that separately.)

Why Does This Matter?

Here is a real situation: A doctor prescribes the same antibiotic at the same dose to two patients - one healthy 30-year-old and one 70-year-old with kidney failure. The 70-year-old ends up with drug toxicity. Why? Because their kidneys cannot remove the drug. The drug accumulates. This is pharmacokinetics in action.

Doctors need pharmacokinetics to:

Choose the right dose
Choose the right route (tablet, injection, inhaler)
Choose the right dosing interval (every 6 hours, every 24 hours)
Predict what happens when a patient has kidney disease, liver disease, or is elderly
Understand drug interactions
Avoid toxicity

Pharmacists need pharmacokinetics to:

Verify whether prescribed doses are safe
Adjust doses for special populations
Counsel patients on timing (with food or without food)
Understand why some drugs cannot be taken orally
Identify clinically dangerous drug interactions

The central question pharmacokinetics answers:

"What does the body do to the drug?"

The ADME Framework

When a drug enters the body, it goes through four major processes. These are so universal that every pharmacology textbook in the world uses the same abbreviation:

Letter	Process	Simple meaning
A	Absorption	Drug enters the blood
D	Distribution	Drug spreads through the body
M	Metabolism	Body chemically changes the drug
E	Excretion/Elimination	Body removes the drug

Think of ADME as the drug's life story inside your body. Each chapter will be taught in full below.

SECTION 2: BUILD THE FOUNDATION - THE PHYSIOLOGY YOU MUST KNOW FIRST

Before you can understand pharmacokinetics, you must understand the roads, barriers, and machinery the drug will encounter inside the body.

2.1 The Cell Membrane - The Drug's First Obstacle

What is it?

Every cell in your body is surrounded by a thin wall called the cell membrane (also called the plasma membrane). It is made of a double layer of fat-like molecules called phospholipids - this arrangement is called the phospholipid bilayer.

The Analogy - Security Gate at an Airport

Imagine an airport security gate. Most travelers (drugs) can walk through if they have the right properties. Some are stopped and must go through a special channel. Others are actively pushed out. The cell membrane works exactly like this.

The Science

The phospholipid bilayer has:

A fatty (hydrophobic, water-hating) core in the middle
Water-loving (hydrophilic) heads on both outer surfaces

This means:

Fat-soluble (lipophilic) drugs can pass through the membrane easily - they dissolve in the fatty core
Water-soluble (hydrophilic) drugs cannot pass through the fatty core - they need help (protein channels, carriers, or active transport)

Why This Matters Clinically

This is the single most important concept governing drug absorption and distribution. A drug that cannot cross membranes cannot be absorbed orally. It cannot enter cells to reach its target. Understanding membrane permeability explains everything from why nitroglycerin is given under the tongue to why some antibiotics cannot enter the brain.

Methods of Crossing Membranes

Method	What happens	Examples
Passive diffusion	Drug dissolves through the membrane (no energy needed)	Most orally absorbed drugs
Facilitated diffusion	Carrier protein helps drug cross (no energy)	Some nutrients
Active transport	Energy (ATP) used; drug moved against concentration gradient	Levodopa, some penicillins
Endocytosis	Membrane engulfs the drug	Vitamin B12
P-glycoprotein efflux	Pump actively throws drug OUT of cells	Reduces absorption of paclitaxel, digoxin

The Henderson-Hasselbalch Concept - Ion Trapping

Most drugs are either weak acids or weak bases. Their ability to cross membranes depends on how much of the drug exists in its un-ionized (non-charged) form at a given pH.

Un-ionized = lipid-soluble = crosses membranes easily
Ionized = water-soluble = trapped, cannot cross membranes

The rule:

Weak acids are better absorbed in acidic environments (stomach, pH 1-2)
Weak bases are better absorbed in alkaline environments (small intestine, pH 5-7)

Clinical trap: Despite being weak acids, most drugs are actually better absorbed in the small intestine than the stomach. Why? Because the stomach has a tiny surface area and fast emptying. The small intestine has a massive surface area (equivalent to a tennis court) and a rich blood supply. The villi and microvilli amplify absorption enormously. Surface area wins over pH, in most cases.

2.2 Body Fluid Compartments - Where Drugs Distribute

The body's fluid is divided into compartments. Understanding them explains why different drugs distribute differently.

TOTAL BODY WATER = ~60% of body weight (42 L in a 70 kg person)
│
├── INTRACELLULAR FLUID (ICF) = 40% of body weight (28 L)
│   (Inside cells)
│
└── EXTRACELLULAR FLUID (ECF) = 20% of body weight (14 L)
    │
    ├── Plasma = 5% of body weight (3.5 L)
    │   (Inside blood vessels, contains proteins)
    │
    └── Interstitial fluid = 15% of body weight (10.5 L)
        (Around cells, outside blood vessels)

Special compartments:

Fat tissue (0.2-0.35 L/kg)
Bone (0.07 L/kg)
Transcellular fluids (CSF, synovial fluid, aqueous humour)

Why this matters:

A drug that stays only in plasma has a small volume of distribution
A drug that goes into fat tissue or muscle has a very large volume of distribution
Knowing where a drug goes tells you how much drug to give and how often

2.3 Blood Circulation - The Drug Highway

Once absorbed, drugs travel in the blood. Here is the circuit:

GUT WALL → PORTAL VEIN → LIVER (first-pass metabolism!)
                              ↓
                    SYSTEMIC CIRCULATION
                              ↓
                   HEART → LUNGS → HEART
                              ↓
                ARTERIES → CAPILLARIES → ORGANS
                              ↓
                           VEINS
                              ↓
                     Back to HEART and LUNGS

The portal circulation is the most important pharmacokinetic concept in absorption: all blood from the intestines drains through the portal vein to the liver BEFORE reaching the heart. This means orally administered drugs must pass through the liver first - creating the first-pass effect.

2.4 The Liver - The Chemical Factory

The liver is the master drug-processing organ. It:

Receives drug-rich blood from the portal vein
Contains cytochrome P450 (CYP) enzymes that chemically modify drugs
Can convert active drugs to inactive metabolites (terminating drug action)
Can convert inactive prodrugs to active drugs (initiating drug action)
Can excrete drugs into bile (entering the gut)

The Analogy - A Factory with Quality Control

Imagine a factory that receives raw materials (drugs) from the port (portal vein). The factory processes them - some are made into finished goods (active metabolites), some are broken down into waste (inactive metabolites), and some are sent out through the back door into the garbage (bile). Only processed products leave through the main gate into general circulation.

Blood flow to the liver: ~1.5 L/min (25% of cardiac output). This high flow rate means the liver has enormous capacity to extract and process drugs.

2.5 The Kidneys - The Water Filtration Plant

The kidneys are the primary route of drug excretion. They work in three ways:

Glomerular filtration - blood is filtered through tiny sieves (glomeruli); free drug (not bound to protein) passes into the filtrate
Tubular secretion - active transport pumps move drugs from blood INTO the tubule (even protein-bound drugs can be secreted this way)
Tubular reabsorption - lipid-soluble, un-ionized drugs diffuse back from tubule INTO blood, reducing excretion

The Analogy - A Water Filtration Plant

Think of the kidney as a water treatment plant. Water (blood) comes in. Garbage (drugs and waste products) is filtered out, processed, and some garbage that should stay in is retrieved (reabsorbed), while the rest goes down the drain (excreted in urine).

Normal GFR: ~120 mL/min/1.73 m²

Clinical importance: Drugs cleared by the kidneys accumulate in renal failure. Gentamicin, vancomycin, digoxin, metformin - all require dose adjustment in renal impairment.

2.6 The Gastrointestinal Tract - The Absorption Corridor

The GI tract is the main route of drug absorption after oral administration. Key features:

Segment	pH	Surface Area	Key Role
Stomach	1-2	Small	Dissolution of tablets, limited absorption
Duodenum	5-6	Medium	Absorption begins
Jejunum	6-7	Enormous (villi)	Primary site of absorption
Ileum	7-8	Large	Further absorption
Colon	7-8	Moderate	Water, some drugs (rectal route)

Key concept - Gastric emptying: The faster the stomach empties, the faster the drug reaches the small intestine, and the faster it is absorbed. Food slows gastric emptying. This is why some drugs must be taken on an empty stomach.

2.7 Plasma Protein Binding - The Drug Taxi Service

Once in the blood, drugs can bind to proteins - mainly albumin (for acidic drugs) and alpha-1-acid glycoprotein (AAG) (for basic drugs).

The Analogy - Buses on a Highway

Imagine drugs as passengers traveling on a highway (bloodstream). Some passengers ride in buses (plasma proteins). Passengers sitting in buses cannot get off at stops (cannot enter tissues, cannot be filtered by kidneys, cannot be metabolized). Only free passengers (unbound drug) can exit the highway and do their job.

Key rules:

Only free (unbound) drug is pharmacologically active
Only free drug can be filtered at the glomerulus
Only free drug can reach its target receptor
Protein-bound drug is an inactive reservoir

Clinical importance:

Hypoalbuminemia (liver disease, malnutrition, nephrotic syndrome) → less protein binding → more free drug → enhanced effect and toxicity at same dose
Drug interactions: if two highly protein-bound drugs compete for the same binding site, one displaces the other → sudden increase in free drug → potential toxicity (e.g., warfarin + aspirin)

SECTION 3: TEACH EACH CONCEPT STEP BY STEP

CONCEPT 1: DRUG ABSORPTION

Definition

Absorption is the movement of a drug from its site of administration into the systemic circulation (bloodstream).

Why It Exists

Drugs need to reach their target. Unless injected directly into the bloodstream, every drug must cross at least one barrier to be absorbed. The body does not automatically accept drugs - they must earn entry.

The Analogy - Getting Through Customs

Swallowing a pill is like arriving at an airport from a foreign country. You (the drug) go through customs (the gut wall, the liver). Some travelers sail through. Others are stopped, searched, and turned back. The fraction that makes it through and gets into the country is the drug's bioavailability.

Factors Affecting Absorption

1. Physicochemical Properties of the Drug

Molecular size: smaller molecules cross membranes better
Lipid solubility: more lipid-soluble = better passive absorption
Ionization: un-ionized form crosses membranes; pH determines this (Henderson-Hasselbalch)
Formulation: tablet vs. capsule vs. liquid vs. slow-release; dissolution rate affects absorption rate

2. Physiological Factors

Gastric pH: affects ionization; achlorhydria (↓ acid) reduces absorption of acid-requiring drugs like iron, ketoconazole
Gastric emptying rate: faster emptying → faster absorption (most drugs absorbed in intestine)
Intestinal motility: too fast (diarrhea) → reduced absorption time; too slow → prolonged absorption
Splanchnic blood flow: reduced in heart failure → reduced absorption
Intestinal surface area: reduced after bowel resection → reduced absorption
First-pass metabolism (see below)

3. Drug-Drug and Drug-Food Interactions

Antacids bind tetracyclines and quinolones → chelation → reduced absorption
Milk binds tetracyclines (calcium chelation)
Food increases absorption of some drugs (fat-soluble vitamins, griseofulvin) and decreases others
P-glycoprotein inducers (rifampicin) reduce gut absorption of co-administered drugs

Common Student Mistake

"Absorption means the drug is working." NO. A drug can be absorbed but immediately metabolized by the liver before reaching its target. Absorption just means it entered the bloodstream from the gut - not that it reached its site of action. This is why bioavailability is the more clinically relevant measurement.

High-Yield Points

Most oral drug absorption occurs in the small intestine (not the stomach)
Passive diffusion is the dominant mechanism for most drugs
Lipophilic, un-ionized forms of drugs cross membranes best
P-glycoprotein in the gut wall actively pumps drugs back out - a major source of reduced absorption

CONCEPT 2: ROUTES OF ADMINISTRATION

Why Routes Matter

Different routes produce different absorption rates, different bioavailabilities, and different clinical effects. Choosing the wrong route can mean a drug fails to work, works too slowly, or causes unnecessary harm.

Complete Table of Routes

Route	Bioavailability	Onset	First-Pass	Clinical Use
Intravenous (IV)	100% (by definition)	Seconds	Absent	Emergencies, precise dosing
Intramuscular (IM)	~100% (variable)	Minutes	Absent	Vaccines, antibiotics
Subcutaneous (SC)	Near 100%	Slower than IM	Absent	Insulin, heparin
Oral (PO)	Variable (0-100%)	30-60 min	Present	Most drugs
Sublingual (SL)	High (avoids first-pass)	Minutes	Absent	Nitroglycerin, GTN
Buccal	High	Minutes	Absent	Some hormone preparations
Rectal	Variable	15-30 min	Partial	Unconscious patients, vomiting
Inhalation	High (large surface area)	Very fast	Absent	Bronchodilators, anaesthetics
Transdermal	Low-moderate	Hours	Absent	Fentanyl patches, nicotine patches
Intrathecal	100% (direct)	Immediate	N/A	CNS infections, anaesthesia
Topical	Minimal systemic	Local	Absent	Skin conditions

Why Sublingual Nitroglycerin Is a Classic Example

Nitroglycerin for angina is given sublingually for very specific pharmacokinetic reasons:

The sublingual mucosa has rich blood supply
Drug passes directly into systemic veins - BYPASSES the portal system and liver
Therefore, avoids first-pass metabolism
Oral nitroglycerin has <10-20% bioavailability because the liver destroys it almost completely before it reaches systemic circulation
Sublingual GTN reaches therapeutic levels within minutes and lasts 15-30 minutes

(Source: Katzung, Chapter on Nitrates)

CONCEPT 3: BIOAVAILABILITY

Definition (Age 9 Level)

If you give 100 mg of a drug orally and only 70 mg actually makes it into the blood unchanged, the bioavailability is 70%.

Formal Definition

Bioavailability (F) is the fraction (or percentage) of an administered dose that reaches the systemic circulation in its unchanged, active form.

Formula:

F = AUC (oral) / AUC (IV) × 100%

Where AUC = Area Under the Curve of a plasma concentration-time graph.

IV route: F = 100% (by definition - drug is directly in the blood)
Oral route: F can range from <5% (drugs with heavy first-pass) to ~100% (drugs like amoxicillin)

The AUC Graph

Plasma
Conc.                IV (100% AUC)
(mg/L)       /\
            /  \
           /    \--------
          /      \       \___
         /        \          \___
--------+----------+---------------→ Time

         Oral (smaller AUC = lower F)
              /\
             /  \
            /    \
           /      \_______
          /               \_____
---------+-------------------------→ Time

The ratio of the areas under both curves = bioavailability.

Why Bioavailability Varies

First-pass metabolism (the most important reason) - see below
Poor absorption (low lipid solubility, large molecular size)
Gut wall metabolism (CYP3A4 in intestinal cells)
P-glycoprotein efflux (pumped out of gut cells)
Incomplete dissolution of tablet formulation
Chemical degradation in gastric acid (penicillin G, insulin)
Chelation with food/antacids

Clinical Importance

When switching a patient from IV to oral, you must account for bioavailability. If oral bioavailability is 50%, you must double the oral dose to achieve the same plasma concentration as the IV dose.

Example: Morphine - IV to oral conversion requires 3x the dose because oral bioavailability is only ~33%.

Common Student Mistake

"IV has better bioavailability, so IV is always better." No. Bioavailability is ONE parameter. Oral is safer, cheaper, and convenient. IV is used when rapid action is needed, when oral absorption is too low, or when the patient cannot swallow.

CONCEPT 4: FIRST-PASS METABOLISM (Hepatic First-Pass Effect)

Definition (Age 9 Level)

When you swallow a drug, it goes from your gut into a special blood vessel (the portal vein) that leads directly to the liver. The liver is so good at destroying certain drugs that before the drug even gets a chance to reach your heart and the rest of your body, a lot of it has already been broken down. This is the first-pass effect.

Formal Definition

First-pass metabolism is the biotransformation of a drug by the intestinal wall and/or liver after oral absorption, but BEFORE it reaches the systemic circulation, resulting in reduced bioavailability.

The Anatomy That Creates It

ORAL DRUG
    ↓
STOMACH + SMALL INTESTINE
    ↓ (absorption)
PORTAL VEIN  ← This is the key anatomical structure
    ↓
LIVER  ← Drug is metabolized here FIRST
    ↓ (only surviving fraction enters systemic blood)
HEART → SYSTEMIC CIRCULATION → EFFECT

The gut wall also contributes: CYP3A4 enzymes in intestinal enterocytes metabolize some drugs before they even reach the portal vein.

Classic Examples of High First-Pass Drugs

Drug	Oral Bioavailability	Why Low?
Nitroglycerin	<10-20%	Almost completely destroyed by liver organic nitrate reductase
Morphine	~33%	Extensive hepatic conjugation
Lidocaine	~35%	High hepatic extraction
Propranolol	~25% (variable)	High hepatic extraction
Testosterone	Very low	Extensive first-pass
Isosorbide mononitrate	~100%	Escapes first-pass (a metabolite of isosorbide dinitrate)

How to Bypass First-Pass Metabolism

Route	How it bypasses
IV/IM/SC	Goes directly to systemic circulation
Sublingual/buccal	Drains into jugular vein, not portal vein
Transdermal	Absorbed through skin into systemic veins
Rectal (partially)	Lower rectum drains to systemic veins; upper rectum still drains to portal
Inhalation	Absorbed through pulmonary capillaries

High-Yield Viva Point

Why is sublingual GTN used instead of oral? - Oral GTN has bioavailability <10-20% due to the first-pass effect. Sublingual GTN bypasses the portal circulation and achieves therapeutic plasma levels within minutes. (Katzung, Goodman & Gilman)

CONCEPT 5: DRUG DISTRIBUTION

Definition

Distribution is the reversible transfer of a drug from the systemic circulation into the tissues and organs of the body.

The Analogy - Hotel Guests

Imagine you release 1000 party guests (drug molecules) into a hotel lobby (bloodstream). Some guests stay in the lobby. Some go to the bar (muscle). Some go to the swimming pool (fat tissue). Some go to the penthouse (brain). Some check out immediately (kidneys). The number of rooms you would need if you evenly spread all the guests throughout the hotel represents the Volume of Distribution.

Factors Affecting Distribution

1. Lipid Solubility

High lipid solubility → drug crosses membranes easily → wide distribution into tissues
Example: Thiopental (highly lipophilic) rapidly enters the brain

2. Plasma Protein Binding

High protein binding → drug stays in plasma → limited distribution
Low protein binding → drug freely enters tissues → wide distribution

3. Tissue Binding

Some drugs bind strongly to specific tissues (e.g., iodine concentrates in thyroid; chloroquine concentrates in melanin-containing tissues)

4. Blood-Brain Barrier (BBB)

A special tight-junction barrier around brain capillaries
Only lipid-soluble, small, un-ionized drugs can cross easily
Penicillin cannot cross the normal BBB; but inflamed meninges (meningitis) open the BBB enough to allow some penetration

5. Placental Barrier

Like the BBB, it is not impenetrable
Lipid-soluble drugs cross easily (thiopental → fetal anaesthesia)
Can cause teratogenicity (thalidomide, warfarin, isotretinoin)

6. pH Partitioning Between Compartments

Weakly basic drugs (e.g., morphine) accumulate in acidic environments (like inflamed tissue or intracellular organelles)

CONCEPT 6: VOLUME OF DISTRIBUTION (Vd)

Definition (Age 9 Level)

Imagine you pour a dye into a swimming pool and measure how diluted it becomes. If the concentration is very low, you know the pool is very large. Now imagine instead of a pool, it is your body. Volume of distribution (Vd) is the imaginary "size of the pool" that explains how diluted the drug becomes after you give a known dose.

Formal Definition

Volume of Distribution (Vd) is the hypothetical volume of fluid in which the total amount of drug would need to be dissolved to produce the observed plasma concentration.

Formula:

Vd = Amount of drug in body (mg)
     ─────────────────────────────
     Plasma drug concentration (mg/L)

     Units: Litres or L/kg

This is an APPARENT volume - it does not correspond to any real anatomical compartment.

Interpreting Vd

Vd	What it means	Example drug
~3-5 L	Drug stays mainly in plasma	Large molecules (antibodies, heparin)
~15 L	Distribution in extracellular fluid	Gentamicin (polar, large)
~40 L	Distribution in total body water	Ethanol (small, water-soluble)
>100 L	Extensive tissue binding	Chloroquine (Vd ~200-800 L/kg!)
Vd >42 L	Drug accumulates in tissues	Digoxin (Vd ~500 L)

(Based on Katzung Table 3-2)

The Hotel Analogy Revisited

A drug with Vd = 40 L distributes evenly in total body water - like guests who go to every room equally. A drug with Vd = 500 L concentrates heavily in tissues - like guests who all flee from the lobby to the deepest basement rooms. If you measure the lobby concentration, it will be very low, making you think you need a hotel 500 L in size, which is impossible in reality.

Clinical Importance of Vd

1. Loading dose calculation:

Loading Dose = Vd × Target plasma concentration

If a drug has a very large Vd, you need a very large loading dose to quickly achieve target plasma levels.

2. Dialysis effectiveness:

A drug with large Vd (e.g., digoxin, Vd ~500 L) is NOT effectively removed by dialysis. Why? Because most of the drug is in tissues, not in the plasma being filtered.
A drug with small Vd (e.g., lithium, Vd ~0.8 L/kg) IS removed by dialysis.

3. Obesity:

Lipophilic drugs have a larger Vd in obese patients
Water-soluble drugs have a relatively smaller Vd
Dose adjustment needed: loading dose of lipophilic drugs like thiopental must be increased in obese patients

CONCEPT 7: DRUG METABOLISM (BIOTRANSFORMATION)

Definition

Drug metabolism (also called biotransformation) is the chemical modification of a drug by enzymes in the body, primarily in the liver.

Why Does the Body Metabolize Drugs?

The body does not recognize drugs as "medicines." It recognizes them as foreign chemicals (xenobiotics). The same systems that evolved to detoxify natural poisons attempt to eliminate drugs. The liver converts lipophilic drugs into water-soluble metabolites that can be excreted by the kidneys. (Lipophilic drugs would otherwise be reabsorbed in the renal tubules instead of being excreted.)

The Analogy - Factory with Two Assembly Lines

The liver is a chemical factory. It has two assembly lines:

Phase I: The machine that cracks open the drug molecule and adds a new chemical handle (usually -OH)
Phase II: The machine that attaches a big, heavy tag (glucuronic acid, sulfate) to the drug, making it heavy enough to fall out of the body (excretion)

PHASE I REACTIONS

What they are:

Phase I reactions chemically MODIFY the drug - usually by introducing or exposing a functional group (-OH, -NH₂, -COOH, -SH).

Main reactions:

Oxidation (most common) - adds oxygen
Reduction - adds hydrogen, removes oxygen
Hydrolysis - splits molecule with water

The Cytochrome P450 System

Most Phase I oxidations are carried out by the cytochrome P450 (CYP) enzyme family, located mainly in:

Liver (highest concentration)
Intestinal wall
Lungs, kidneys, adrenals (minor)

CYP enzymes are named by family number, subfamily letter, and enzyme number:

CYP3A4 - the most important: metabolizes ~50% of all drugs (midazolam, cyclosporin, many statins, most calcium channel blockers, many antibiotics)
CYP2D6 - metabolizes ~25% of drugs (codeine, tramadol, beta-blockers, many antidepressants)
CYP2C9 - warfarin, phenytoin, NSAIDs
CYP2C19 - omeprazole, clopidogrel, diazepam
CYP1A2 - theophylline, caffeine, clozapine

Results of Phase I Metabolism:

Result	Meaning	Example
Active drug → Inactive metabolite	Termination of effect	Diazepam → oxazepam (partly)
Active drug → Active metabolite	Continuation of effect	Codeine → morphine (active, more potent)
Prodrug → Active drug	Activation	Enalapril → enalaprilat; Clopidogrel → active thiol metabolite
Active drug → Toxic metabolite	Dangerous!	Paracetamol → NAPQI (toxic with overdose)

Clinical Pearl - Codeine and Genetics: Codeine is converted to morphine by CYP2D6.

Ultra-rapid metabolizers: convert too much → morphine toxicity, even respiratory depression in infants via breastmilk
Poor metabolizers (PMs): convert too little → no pain relief from codeine

PHASE II REACTIONS (Conjugation Reactions)

What they are:

Phase II reactions attach a large, water-soluble molecule to the drug (or Phase I metabolite), making it polar enough to be excreted in urine or bile.

Main conjugation reactions:

Reaction	Endogenous substrate added	Enzyme	Example
Glucuronidation	Glucuronic acid (UDP-glucuronate)	UGT enzymes	Morphine → M-6-G and M-3-G; paracetamol
Sulfation	Sulfate	Sulfotransferases	Paracetamol; steroids
Acetylation	Acetyl group	NAT (N-acetyl transferase)	Isoniazid, hydralazine, dapsone
Methylation	Methyl group	Methyltransferases	Catecholamines, histamine
Glycine conjugation	Glycine	-	Salicylates, nicotinic acid
Glutathione conjugation	Glutathione	GST	Paracetamol (protects against NAPQI)

Most important: Glucuronidation - the most common and most important Phase II reaction. Products are water-soluble and excreted in bile or urine.

Notable exception: Morphine-6-glucuronide (M-6-G) is MORE potent than morphine itself. This is clinically significant: in renal failure, M-6-G accumulates and can cause prolonged respiratory depression.

Neonates: Neonates have immature UGT enzymes. They cannot glucuronidate drugs well. This explains:

Chloramphenicol toxicity in newborns (Grey Baby Syndrome) - cannot conjugate chloramphenicol
Jaundice (cannot conjugate bilirubin)

CONCEPT 8: ENZYME INDUCTION AND ENZYME INHIBITION

Why These Are the Most Clinically Dangerous Concepts in Pharmacokinetics

Drug interactions involving CYP enzymes kill patients. Understanding induction and inhibition can prevent serious clinical harm.

ENZYME INDUCTION

Definition

Enzyme induction is the process by which a drug (or other substance) increases the synthesis of metabolic enzymes, leading to increased metabolism of other drugs.

Analogy - Factory Hiring More Workers

Imagine your liver factory normally has 10 workers. A drug (the inducer) arrives and tells the factory to hire 100 more workers. Now all drugs that come through the factory are processed much faster - they are metabolized and eliminated more quickly. Less drug reaches the bloodstream. Effect is reduced.

Consequences:

Reduced plasma levels of co-administered drugs
Reduced efficacy (therapeutic failure)
Important: Induction takes days to weeks (because new enzyme protein must be synthesized)

Classic Enzyme Inducers (Mnemonic: PC BRAS):

Phenytoin
Carbamazepine
Barbiturates (phenobarbitone)
Rifampicin (most potent clinical inducer)
Alcohol (chronic)
St. John's Wort (herbal - be careful!)

Clinical Examples of Induction:

Rifampicin + warfarin → INR falls → patient's blood clots (warfarin metabolized faster)
Rifampicin + oral contraceptive pill → OCP fails → unintended pregnancy
Carbamazepine + phenytoin → both induce each other → levels drop → seizures
Phenobarbitone + phenytoin → reduced anticonvulsant effect

ENZYME INHIBITION

Definition

Enzyme inhibition is when a drug reduces the activity of metabolic enzymes, leading to decreased metabolism of other drugs → drug accumulates → toxicity.

Analogy - Factory Workers Go on Strike

The inhibitor drug walks into the factory and all workers go on strike (or get sent home). Now drugs pile up - they are not metabolized. Their plasma levels rise and effects intensify. At the same time, prodrugs are not converted to active form - they may fail.

Consequences:

Increased plasma levels of co-administered drugs
Toxicity risk
Important: Inhibition is RAPID - happens as soon as the inhibitor is present (no protein synthesis needed, unlike induction)

Classic Enzyme Inhibitors (Mnemonic: CRAKI - "Crazy Inhibitors"):

Clarithromycin / Cimetidine
Ritonavir (most potent) - used therapeutically to "boost" other HIV drugs
Azole antifungals (ketoconazole, fluconazole, itraconazole)
Ketoconazole
Isoniazid (inhibits CYP2C9, CYP3A4)
Erythmomycin, Grapefruit juice (CYP3A4 inhibitor in gut wall!)

(From Lippincott, Chapter 1)

Clinical Examples of Inhibition:

Fluconazole + warfarin → warfarin level doubles → bleeding risk
Clarithromycin + simvastatin → statin level rises → rhabdomyolysis
Ritonavir + many drugs → accumulation → toxicity (reason ritonavir is given at low doses to boost other PIs)
Grapefruit juice + simvastatin/felodipine → markedly increased drug levels (drink water with your medication!)

CONCEPT 9: DRUG EXCRETION

Definition

Excretion (also called elimination) is the irreversible removal of drug or drug metabolites from the body.

Routes of Excretion:

Route	Importance	Drug examples
Renal (kidney)	Most important	Most water-soluble drugs and metabolites
Biliary/Fecal	Second most important	Large molecular weight drugs, glucuronide conjugates
Pulmonary (lungs)	Volatile drugs	Volatile anaesthetics, ethanol (breathalyser)
Saliva	Minor	Lithium, digoxin
Breast milk	Clinically important!	Many drugs - risk to breastfed infant
Sweat/skin	Negligible

RENAL EXCRETION - In Detail

Three processes occur in the kidney:

1. Glomerular Filtration

Occurs passively through the glomerular capillary slits
Only free (unbound) drug is filtered - protein-bound drug is too large to pass
Filtration rate is proportional to GFR (~120 mL/min normally)
NOT affected by lipid solubility or pH

2. Active Tubular Secretion

Occurs in the proximal tubule
Requires energy (ATP); uses carrier proteins (transporters OAT, OCT, MDR1)
Can transport even protein-bound drug (the drug is released from albumin and secreted)
Two systems:
- Organic Acid (Anion) Transporter: excretes acidic drugs (penicillin, methotrexate, probenecid)
- Organic Base (Cation) Transporter: excretes basic drugs (morphine, quinine, dopamine)
Drug interaction: Probenecid competes with penicillin for tubular secretion → penicillin stays in blood longer (historically used therapeutically to maintain penicillin levels)

3. Tubular Reabsorption

Occurs along the entire tubule
Passive diffusion of lipid-soluble, un-ionized drug back into blood
Reduces net excretion
pH of urine determines how much reabsorption occurs:
- Weak acid drug + alkaline urine → drug stays ionized → stays in tubule → MORE excretion
- Weak acid drug + acidic urine → drug stays un-ionized → gets reabsorbed → LESS excretion

Clinical application - Ion Trapping for Overdose Treatment:

Aspirin (salicylate) overdose: Give sodium bicarbonate → alkalinize urine → salicylate stays ionized in tubule → trapped → excreted in urine
Amphetamine (basic drug) overdose: Give ammonium chloride → acidify urine → amphetamine stays ionized → excreted

Net Renal Excretion

Renal Excretion = Filtration + Secretion - Reabsorption

Renal Clearance

Renal Clearance (CLr) = rate of elimination by kidney / plasma concentration

For most drugs: CLr ≤ GFR (filtration + partial reabsorption) For actively secreted drugs: CLr > GFR (secretion adds to filtration) Maximum possible CLr by secretion is ~650 mL/min (penicillin approaches this)

BILIARY EXCRETION AND ENTEROHEPATIC CIRCULATION

Some drugs are excreted by the liver into bile, then into the duodenum (via the bile duct). If the drug is then reabsorbed from the gut, it re-enters the portal circulation and goes back to the liver - a cycle called enterohepatic circulation.

LIVER → BILE DUCT → DUODENUM → SMALL INTESTINE
                                        ↓
                               (Reabsorption occurs)
                                        ↓
                              PORTAL VEIN → LIVER (cycle continues)

Consequence: Drugs with enterohepatic circulation have:

Prolonged duration of action
Higher total body load than expected
Disrupted excretion if gut flora is altered (antibiotics can break the cycle by killing bacteria that deconjugate glucuronides, preventing reabsorption)

Examples: Ethinylestradiol (OCP), morphine glucuronides, digoxin, indomethacin

Clinical implication: Some antibiotics reduce OCP efficacy by disrupting enterohepatic cycling of ethinylestradiol (controversial, but clinically acknowledged).

CONCEPT 10: CLEARANCE

Definition (Age 9 Level)

Clearance is the volume of plasma that is completely cleared of drug per unit time.

Formal Definition

Clearance (CL) is the volume of plasma from which a drug is irreversibly removed per unit time.

Formula:

CL = Rate of elimination / Plasma concentration
   = Vd × Kel
   = (0.693 × Vd) / t½

Units: mL/min or L/hr

Clearance is Additive:

Total CL = CLrenal + CLhepatic + CLother

Analogy - The Drain on a Bathtub Think of the bathtub as the body, and the water level as drug concentration. Clearance is the size of the drain. A large drain (high clearance) empties the tub quickly. A small drain (low clearance) empties it slowly. Adding a second drain (renal + hepatic) means water drains faster.

Hepatic Clearance and the Extraction Ratio

Hepatic Extraction Ratio (E) = the fraction of drug removed from blood in a single pass through the liver.

Extraction Ratio	Type	Drug	Hepatic CL depends on...
High (E > 0.7)	High extraction	Morphine, propranolol, lidocaine	Liver blood flow (perfusion-limited)
Low (E < 0.3)	Low extraction	Warfarin, diazepam, phenytoin	Enzyme capacity + protein binding (capacity-limited)

Clinical implication:

High extraction drugs: decreased liver blood flow (heart failure, cirrhosis) → reduced clearance → drug accumulates
Low extraction drugs: liver enzyme activity (induction/inhibition) determines clearance; blood flow is not the limiting factor

CONCEPT 11: HALF-LIFE (t½)

Definition (Age 9 Level)

Half-life is the time it takes for the amount (or concentration) of drug in your body to fall by half.

Formal Definition

Elimination half-life (t½) is the time required for the plasma concentration of a drug to decrease by 50%.

Formula:

t½ = 0.693 × Vd
     ─────────────
          CL

     (0.693 = ln 2)

What Happens Over Multiple Half-Lives?

Starting with 100% drug:

Number of half-lives	Drug remaining
1	50%
2	25%
3	12.5%
4	6.25%
5	3.12%
5 half-lives	~97% eliminated

Rule: A drug is effectively eliminated after 5 half-lives.

The Graph - Plasma Concentration vs Time

Plasma
Conc.   100 ──•
               \
          50    •── (1 t½)
                 \
          25      •── (2 t½)
                   \
          12.5      •── (3 t½)
                     \
           6.25        •── (4 t½)
                        \
           3.12           •── (5 t½)
────────────────────────────────────→ Time

This is an exponential decay (first-order kinetics).

Types of Kinetics

Type	What changes	Rate formula	Example
First-order (linear)	Rate proportional to drug concentration	Rate = k × C	Most drugs at therapeutic doses
Zero-order (non-linear, saturation)	Rate constant (fixed amount per time) regardless of concentration	Rate = constant	Alcohol, aspirin at high doses, phenytoin

First-order: If you double the dose, the plasma concentration at steady state doubles. Zero-order: Enzymes are saturated. Any increase in dose leads to disproportionately large increases in plasma concentration - extremely dangerous (phenytoin toxicity).

Clinical Importance of t½:

Determines dosing interval: drugs are usually dosed every t½ (or every 1-2 t½)
Predicts time to steady state: ~4-5 t½ to reach steady state
Predicts time to offset of drug effect: clinically useful when stopping a drug
Guides timing of drug levels: measure trough levels just before next dose

Examples of clinically important half-lives:

Drug	t½	Clinical implication
Insulin (regular)	~5 min	Given by continuous infusion or frequent SC injections
Penicillin G	~30 min	Must be given every 4-6 hours (or by infusion)
Aspirin	~15-20 min (aspirin itself)	But effect on platelets lasts 7-10 days (irreversible)
Atenolol	~6-7 hours	Once or twice daily
Digoxin	~36-40 hours	Once daily; accumulates in renal failure
Amiodarone	~40-55 days	Weeks to months to fully eliminate; drug interactions persist long after stopping

CONCEPT 12: STEADY-STATE CONCENTRATION (Css)

Definition

Steady state is reached when the rate of drug administration equals the rate of drug elimination. At steady state, the plasma concentration fluctuates within a predictable range rather than continuing to rise or fall overall.

Analogy - Filling a Bathtub with a Drain

Turn on the tap (give drug repeatedly). Water (drug) accumulates. But the drain is also running. Eventually, inflow = outflow. The water level stabilizes. That stable level is steady state.

Time to Reach Steady State

Steady state is reached after 4-5 half-lives, regardless of dose or dosing frequency.

More frequent dosing → less fluctuation between doses (smaller peaks and troughs)
Less frequent dosing → more fluctuation (higher peaks, lower troughs)
Dose determines the LEVEL of steady state; dosing interval determines FLUCTUATION

Plasma
Conc.       ___________________________  ← Steady State (Css)
            /\/\/\/\/\/\/\/\/\/\/\/\/\/\/
           /\/\/\/\/\/\/\/\/\/\/\/\/
          /\/\/\/\/\/\/\/
        /\/\/\/
     /\/\
    / \
───────────────────────────────────→ Time
     ↑   ↑   ↑   ↑
   Doses (given every t½ in this example)

Clinical Importance:

When do you first see full therapeutic effect? After 4-5 t½ (steady state)
Why does amiodarone take weeks to work? Because t½ ~40-55 days - takes months to reach steady state
Why does digoxin cause toxicity after a few days? In a normal patient, steady state after ~5-7 days. In renal failure, clearance drops, t½ lengthens → accumulation to toxic levels

CONCEPT 13: LOADING DOSE AND MAINTENANCE DOSE

Loading Dose

Definition

A loading dose is a large initial dose given to rapidly achieve therapeutic plasma concentrations, especially for drugs with long half-lives.

Formula:

Loading Dose = Target Css × Vd
               ────────────────
                       F

(F = bioavailability; for IV, F = 1)

Analogy

You want to fill a swimming pool quickly. Instead of waiting for the normal tap to fill it (which would take days), you use a fire hose for the first hour. That burst of water is the loading dose. Then you switch back to the normal tap (maintenance dose) to keep the level stable.

Clinical Examples:

Digoxin: Long t½ (~36-40 hours). Without loading dose, takes ~7 days to reach steady state. Loading dose achieves effect within hours.
Amiodarone: Extremely long t½. Loading dose given for days before maintenance.
Phenytoin: Given as IV loading dose in status epilepticus for rapid seizure control.
Warfarin: Does NOT need a loading dose (no rapid emergency use). Started at maintenance.

Maintenance Dose

Definition

The maintenance dose is the dose given at regular intervals to maintain steady-state plasma concentration.

Formula:

Maintenance Dose = Target Css × CL × Dosing interval
                   ────────────────────────────────────
                                 F

Or more practically:

Maintenance Dose Rate = Target Css × Total Clearance

Dose Adjustment in Renal/Hepatic Failure:

If clearance is halved (kidney failure) → halve the maintenance dose OR double the dosing interval to maintain same Css
This is why renally cleared drugs need dose reduction in renal failure

SECTION 4: MENTAL PICTURES AND ANALOGIES - CONSOLIDATED

The Master Analogy Map

┌─────────────────────────────────────────────────────────┐
│                   THE DRUG CITY ANALOGY                  │
│                                                         │
│  SWALLOWING DRUG = Arriving at the City Airport         │
│  GUT WALL = Customs at the Airport                      │
│  PORTAL VEIN = Arrivals Highway heading to City Hall    │
│  LIVER (FIRST-PASS) = City Hall: 70% of visitors        │
│                       turned back at the gate           │
│  SYSTEMIC BLOOD = City Streets (the highway system)     │
│  ALBUMIN = Buses on the streets (carry passengers)      │
│  FREE DRUG = Pedestrians who can enter buildings        │
│  PLASMA PROTEIN-BOUND DRUG = Bus passengers who can't   │
│                              get off                    │
│  TISSUES/FAT = Buildings where drug "lives"             │
│  LIVER = Factory that transforms drug molecules         │
│  KIDNEYS = Sewage plant: filters out waste (drug)       │
│  HALF-LIFE = Time for half the city to leave            │
│  STEADY STATE = Population equilibrium in the city      │
│  LOADING DOSE = Opening a new stadium - big surge       │
│  MAINTENANCE DOSE = Normal daily activity               │
└─────────────────────────────────────────────────────────┘

SECTION 5: STEP-BY-STEP CLINICAL THINKING

Clinical Scenario 1: Why IV Drugs Act Faster

IV morphine vs. oral morphine in severe pain:

IV morphine: directly enters systemic circulation → drug immediately travels to brain → pain relief within minutes
Oral morphine: absorbed from gut (30-60 min) → portal vein → liver (first-pass reduces it by ~67%) → systemic circulation → brain
IV onset: 2-5 minutes
Oral onset: 30-60 minutes
To get the same effect, oral morphine dose must be 3× the IV dose

Clinical Scenario 2: Why Oral Drugs May Fail

A patient with severe vomiting needs an antibiotic.

Problem: Oral tablets cannot be retained (vomited). Even if swallowed, gastric emptying is altered. GI mucosal blood flow may be reduced. Drug may not be absorbed.

Solution: Give IV or IM route to bypass GI absorption entirely.

Clinical Scenario 3: Liver Disease and Drug Dosing

A patient with cirrhosis (severe liver scarring) receives morphine.

Normal scenario: Morphine oral bioavailability = ~33% (first-pass) Cirrhosis scenario:

Liver cell mass reduced → fewer CYP enzymes → less first-pass metabolism
Portal hypertension → portosystemic shunting → some blood bypasses liver entirely
Result: Oral bioavailability rises dramatically → standard dose becomes toxic

Action: Reduce morphine dose. Use with caution. Monitor for sedation and respiratory depression.

Clinical Scenario 4: Kidney Disease and Drug Toxicity

A patient with chronic kidney disease (CKD) is on gentamicin.

Gentamicin is eliminated almost entirely by renal filtration
In CKD: GFR falls → gentamicin clearance falls → t½ increases → drug accumulates
Normal t½ of gentamicin: ~2 hours
In severe CKD: t½ may extend to 20-50 hours
Result without dose adjustment: drug accumulates to toxic levels → nephrotoxicity (worsens the very problem you are treating) and ototoxicity (irreversible deafness)

Action: Reduce dose or extend dosing interval. Monitor drug levels (trough levels).

Clinical Scenario 5: Elderly Patients

An 80-year-old patient is started on diazepam for anxiety.

Age-related pharmacokinetic changes:

Parameter	Change with age	Clinical consequence
GI absorption	Slightly reduced	Minor effect
Body fat (%)	Increased	Larger Vd for lipophilic drugs → longer t½
Lean body mass	Decreased	Smaller Vd for water-soluble drugs
Plasma albumin	Decreased	More free drug → enhanced effect
Liver mass/blood flow	Decreased	Reduced hepatic clearance
GFR	Falls ~1 mL/min/year after age 40	Reduced renal clearance

Diazepam in the elderly:

Highly lipophilic → large Vd
Elderly have more fat → even larger Vd
Hepatic metabolism reduced
t½ extends from 20-100 hours in young adults to up to 200 hours in elderly
Result: drug accumulates → prolonged sedation → falls → confusion → aspirin

"Start low, go slow" - the principle for elderly prescribing.

Clinical Scenario 6: Obesity and Drug Distribution

An obese patient (BMI 42) requires anaesthesia with thiopental.

Thiopental is highly lipophilic → large Vd normally
In obesity: even larger fat compartment → Vd is greatly increased
If you calculate loading dose based on ideal body weight → too little drug → inadequate anaesthesia
Must account for increased Vd

General rule:

Lipophilic drugs (thiopental, benzodiazepines, propofol): dose on total body weight (or use lean body weight adjustments)
Hydrophilic drugs (aminoglycosides, vancomycin): dose on ideal body weight (fat does not hold these drugs)

SECTION 6: CONNECTING ALL THE CONCEPTS

The Pharmacokinetic Chain

DOSE GIVEN
     ↓
ABSORPTION
(Route, lipid solubility, first-pass, formulation)
     ↓
BIOAVAILABILITY (F)
     ↓
PLASMA CONCENTRATION
     ↓
DISTRIBUTION (Vd)
(Protein binding, lipid solubility, tissue binding, barriers)
     ↓
DRUG AT RECEPTOR = PHARMACOLOGICAL EFFECT
     ↓ ↑ (constant exchange between blood and tissues)
METABOLISM (Phase I + II)
(CYP enzymes, conjugation, first-pass, enzyme induction/inhibition)
     ↓
WATER-SOLUBLE METABOLITES
     ↓
EXCRETION
(Kidney: filtration + secretion - reabsorption)
(Liver → Bile → Feces)
     ↓
HALF-LIFE and CLEARANCE determine DURATION
     ↓
STEADY STATE with repeated dosing
     ↓
DOSING STRATEGY (Loading dose + Maintenance dose)

Every concept is a link in this chain. A broken link anywhere changes the entire drug profile.

SECTION 7: VISUAL LEARNING

Visual 1: The ADME Flowchart

┌──────────────┐
│  DRUG GIVEN  │
│ (Oral/IV/IM) │
└──────┬───────┘
       │
       ▼
┌──────────────────────────────────────┐
│          ABSORPTION                  │
│  • Dissolution of tablet             │
│  • Crossing gut wall membranes       │
│  • Passive diffusion / Active        │
│  • First-pass effect in liver        │
└──────────────────┬───────────────────┘
                   │ (F fraction enters blood)
                   ▼
┌──────────────────────────────────────┐
│         SYSTEMIC CIRCULATION         │
│  (Plasma + Blood cells)              │
│  Free drug ←→ Protein-bound drug     │
└─────┬──────────────────────┬─────────┘
      │                      │
      ▼                      ▼
┌─────────────┐       ┌──────────────────┐
│ DISTRIBUTION│       │   METABOLISM     │
│             │       │ (LIVER - CYP)    │
│ Tissues     │       │                  │
│ Fat         │       │ Phase I: Oxidize │
│ Muscle      │       │ Phase II: Conjug.│
│ Brain       │       └────────┬─────────┘
│ Organs      │                │
└─────────────┘                ▼
                        ┌──────────────┐
                        │  EXCRETION   │
                        │              │
                        │  Kidneys     │
                        │  (Urine)     │
                        │  Liver→Bile  │
                        │  (Feces)     │
                        │  Lungs       │
                        └──────────────┘

Visual 2: Plasma Concentration-Time Curve (Oral Dose)

Plasma
Conc.
(mg/L)
        Peak (Cmax)
          •
         / \
        /   \         Therapeutic range
  ─────/─────\─────── MEC (minimum effective concentration)
      /       \
     /         \
────/─────────────\──────────────────────────
   /               \______________________
Absorption         Elimination phase
phase              (slope = -Kel = -0.693/t½)

   │──────│          ──── Time
  Tmin   Tmax   Cmax


KEY POINTS ON THIS GRAPH:
• Cmax = Peak plasma concentration
• Tmax = Time to peak concentration
• AUC = Area under the curve = total drug exposure
• MEC = Minimum Effective Concentration (below = no effect)
• MTC = Minimum Toxic Concentration (above = toxicity)
• Therapeutic window = between MEC and MTC

Visual 3: Half-Life and Steady State

Concentration
(% of Steady State)

100% ─────────────────────────────────────────────────
                                             ___________
                                      ______/
90%                              ____/
                            ____/
75%                    ____/
50%               ____/
                _/
0%   ──────────────────────────────────────────────────
     0    1t½   2t½   3t½   4t½   5t½
                                   ↑
                              Steady state
                           (effectively reached)

Visual 4: Comparison Table - Phase I vs Phase II Metabolism

Feature	Phase I	Phase II
Type of reaction	Oxidation, reduction, hydrolysis	Conjugation (attachment)
Main enzymes	CYP450 (liver, gut)	UGT, sulfotransferase, NAT
Main location	Liver ER (microsomes)	Liver cytosol + microsomes
Product polarity	Slightly increased	Greatly increased (very polar)
Product activity	Variable (may still be active, or toxic)	Usually inactive (exceptions: M-6-G)
Sequence	Usually first	Usually second
Drug can skip Phase I?	No (default first)	Yes! If already has -OH, -NH₂, -COOH
Affected by age?	Yes (reduced in elderly, neonates)	Yes (especially glucuronidation in neonates)

SECTION 8: MEMORY TOOLS

Mnemonic 1: ADME = "A Drug Moving Everywhere"

Absorption - "A Drug..."
Distribution - "Moving..."
Metabolism - "Everywhere..."
Excretion - (what's left gets removed)

Mnemonic 2: CYP Enzyme Inducers - "PC BRAS" (the inducers are BIG and POWERFUL like a bra - they hold the enzyme levels up)

Phenytoin
Carbamazepine
Barbiturates
Rifampicin (most potent!)
Alcohol (chronic)
St. John's Wort

Mnemonic 3: CYP Enzyme Inhibitors - "SICKFACES.COM" (classic mnemonic)

Sodium valproate
Isoniazid
Cimetidine
Ketoconazole / Ketoconazole (azole antifungals)
Fluoxetine / Fluconazole
Amiodarone
Clarithromycin (macrolides)
Erythromycin
Sulfonamides
Chloroamphenicol
Omeprazole
Metronidazole

Mnemonic 4: Highly Protein-Bound Drugs - "WAVED" (drugs that can cause displacement interactions)

Warfarin
Aspirin
Valproate
Ethosuximide
Digoxin... plus phenytoin, NSAIDs, sulfonamides

Memory Story: Pharmacokinetics Journey

"Meet Anna Drug. She swallows a pill (Absorption). The pill dissolves in her stomach, travels to her small intestine, and crosses the gut wall. She then takes a taxi (portal vein) to City Hall (the liver). The liver officer (CYP3A4) checks her papers and stamps some of them "DESTROYED" (first-pass). The survivors escape to the main highway (systemic circulation). Some join the bus (plasma proteins). The free ones visit organs (Distribution). The liver factory transforms them (Metabolism). Finally, the kidneys filter them out into the drain (Excretion). After 5 half-lives, Anna is gone."

Rapid Comparison Table: Factors Affecting Pharmacokinetics in Special Populations

Factor	Effect on PK	Clinical adjustment
Renal failure	↓ Clearance of renally cleared drugs, ↑ t½	Reduce dose or extend interval
Liver failure	↓ First-pass, ↓ CYP activity, ↓ albumin	Reduce dose; avoid hepatotoxic drugs
Elderly	↓ GFR, ↓ liver mass, ↑ fat, ↓ albumin	"Start low, go slow"
Obesity	↑ Vd for lipophilic drugs	Use total body weight for lipophilic drugs
Neonates	Immature CYP, immature glucuronidation, larger ECF	Markedly different dosing per kg
Pregnancy	↑ GFR, ↑ volume, altered protein binding	Many drugs need dose adjustment
Heart failure	↓ GI blood flow, ↓ liver perfusion, ↓ renal perfusion	Reduced absorption and clearance

SECTION 9: THE EXAMINER'S CORNER

Most Tested Concepts in Pharmacokinetics (Ranked by Exam Frequency)

First-pass effect / first-pass metabolism - definition, examples, how to bypass
Volume of distribution - definition, formula, clinical use (dialysis, loading dose)
Half-life - definition, formula, relationship to Vd and CL, clinical significance
Enzyme induction - definition, examples (PC BRAS), clinical consequences
Enzyme inhibition - definition, examples (SICKFACES), clinical consequences
Bioavailability - definition, formula, AUC, factors affecting
Protein binding - clinical importance, displacement interactions, hypoalbuminemia
Clearance - definition, formula, hepatic vs renal, extraction ratio
Steady state - concept, time to reach (4-5 t½), loading dose rationale
Renal excretion - three mechanisms (filtration, secretion, reabsorption), ion trapping

Most Repeated Essay Questions

"Describe the pharmacokinetic basis for first-pass metabolism and its clinical significance. Give examples."
"Define bioavailability. What factors affect it? How is it calculated?"
"Describe the phases of drug metabolism with examples. How do enzyme induction and inhibition affect drug therapy?"
"Define Volume of Distribution. What is its clinical significance? How is it used to calculate loading dose?"
"Explain the mechanism and clinical importance of drug-drug interactions at the level of cytochrome P450 enzymes."
"Define half-life and clearance. How are they related? What factors determine each?"

Most Repeated Short Notes (SAQ Topics)

First-pass metabolism
Enzyme induction with examples
Enzyme inhibition with examples
Volume of distribution and its clinical significance
Bioavailability and factors affecting it
Steady-state concentration and loading dose
Renal drug excretion (three mechanisms)
Plasma protein binding - clinical significance
Ion trapping and its clinical application
CYP3A4 and CYP2D6 - substrates, inducers, inhibitors

Most Repeated Viva Questions

"What does the body do to a drug?" → ADME
"Why is sublingual GTN preferred over oral?" → First-pass
"What is bioavailability?" → Formula, AUC
"Why does rifampicin reduce the efficacy of the OCP?"
"What is Vd? What does a large Vd tell you?"
"What is the clinical significance of plasma protein binding?"
"After how many half-lives is a drug effectively eliminated?"
"Why do patients with renal failure need dose adjustment?"
"What is steady state? How long does it take to achieve?"
"Why can't insulin be given orally?"

Most Repeated MCQ Patterns

Question type	Key answer
"Which route completely avoids first-pass?"	IV (and sublingual, inhalation, transdermal)
"Most important site of drug absorption?"	Small intestine
"Bioavailability of IV route?"	100%
"Which parameter is calculated as Dose/Cp₀?"	Volume of distribution
"Most potent CYP enzyme inducer?"	Rifampicin
"Most powerful CYP inhibitor (used therapeutically)?"	Ritonavir
"Time to reach steady state?"	4-5 half-lives
"Formula for t½?"	0.693 × Vd / CL
"Drug with zero-order kinetics?"	Alcohol, phenytoin (at toxic doses), aspirin
"Protein-bound drug cannot be..."	Filtered at glomerulus (but CAN be secreted)
"Grey Baby Syndrome is due to?"	Inability to glucuronidate chloramphenicol (immature UGT)
"Morphine-6-glucuronide is...?"	More potent than morphine (accumulates in renal failure)

Common Examination Traps

Trap 1: "Sublingual route avoids ALL liver metabolism."

FALSE. The drug still reaches the liver via systemic circulation. It just avoids FIRST-PASS metabolism (pre-systemic metabolism).

Trap 2: "Only free drug is metabolized."

TRUE for filtration. But actively secreted drugs can be extracted even when protein-bound (transporter proteins strip them off albumin).

Trap 3: "Rectal route completely avoids first-pass."

PARTIAL. Lower rectal veins drain into inferior vena cava (systemic) - avoiding first pass. Upper rectal veins drain to portal system - first pass occurs.

Trap 4: "A drug with zero-order kinetics has a fixed half-life."

FALSE. Zero-order kinetics means RATE of elimination is constant, not the fraction. Half-life increases as concentration rises (the opposite of first-order kinetics).

Trap 5: "Protein-bound drug is inactive and harmless."

TRUE for pharmacological effect. But protein-bound drug IS part of the total body load and will be released as free drug falls. It is a reservoir, not garbage.

Trap 6: "Enzyme induction increases drug levels."

FALSE. Induction INCREASES metabolism → DECREASES plasma levels of the drug being metabolized (except for prodrugs). This is frequently tested as a trap.

Trap 7: "Loading dose depends on clearance."

FALSE. Loading dose depends on Vd (and target concentration). MAINTENANCE dose depends on clearance.

SECTION 11: HIGH-YIELD REVISION SHEET

Essential Definitions (One Line Each)

Term	Definition
Pharmacokinetics	What the body does to a drug (ADME)
Absorption	Movement of drug from site of administration to systemic circulation
Bioavailability (F)	Fraction of administered dose reaching systemic circulation unchanged
First-pass effect	Pre-systemic metabolism by gut wall and liver, reducing oral bioavailability
Distribution	Reversible transfer of drug from blood to tissues
Volume of distribution (Vd)	Hypothetical volume: Vd = Dose / Plasma concentration
Protein binding	Reversible binding of drug to plasma proteins (only free drug is active)
Metabolism	Enzymatic biotransformation of drug, primarily in liver
Phase I	Oxidation/reduction/hydrolysis (mainly CYP450)
Phase II	Conjugation reactions (glucuronidation, sulfation, acetylation, etc.)
Enzyme induction	Increased synthesis of CYP enzymes → faster drug metabolism → reduced plasma levels
Enzyme inhibition	Reduced CYP enzyme activity → slower metabolism → increased plasma levels
Clearance (CL)	Volume of plasma cleared of drug per unit time
Half-life (t½)	Time for plasma concentration to fall by 50%
Steady state	When rate of administration = rate of elimination
Loading dose	Large initial dose to rapidly achieve target plasma concentration
Maintenance dose	Regular dose to sustain steady-state plasma concentration
First-order kinetics	Rate of elimination proportional to concentration (constant fraction/time)
Zero-order kinetics	Rate of elimination constant regardless of concentration (constant amount/time)
Extraction ratio	Fraction of drug removed in single pass through liver

Essential Formulas

1. Bioavailability:          F = AUC(oral) / AUC(IV)

2. Volume of Distribution:   Vd = Dose / Cp₀

3. Half-life:                t½ = 0.693 × Vd / CL

4. Clearance:                CL = 0.693 × Vd / t½
                             CL = Dose / AUC

5. Loading Dose:             LD = Target Css × Vd / F

6. Maintenance Dose Rate:    MD = Target Css × CL / F

7. Renal Excretion:          = Filtration + Secretion - Reabsorption

8. Time to Steady State:     4-5 × t½

9. % Drug Remaining:         After n half-lives = (0.5)ⁿ × 100%

Most Important Graphs to Know

Plasma concentration-time curve (oral) - showing Cmax, Tmax, AUC, therapeutic window
IV vs oral AUC comparison - showing bioavailability
Exponential elimination curve - first-order kinetics
Steady-state accumulation - drug building up over 4-5 half-lives
Loading dose + maintenance dose - showing rapid achievement of Css

Clinical Pearls

Narrow therapeutic index drugs (digoxin, warfarin, lithium, phenytoin, aminoglycosides, cyclosporin) require therapeutic drug monitoring (TDM) because small changes in PK parameters cause toxicity or failure
Rifampicin is the most potent enzyme inducer in clinical use - responsible for massive drug interactions with OCP, warfarin, antiretrovirals, and many others
Grapefruit juice inhibits intestinal CYP3A4 - dangerous with statins, calcium channel blockers
Morphine-6-glucuronide accumulates in renal failure and is more potent than morphine - cause of prolonged respiratory depression
Codeine is a prodrug - requires CYP2D6 to convert to morphine. Poor metabolizers get no pain relief. Ultra-rapid metabolizers may die from morphine toxicity.
Large Vd = drug is in tissues, not in blood = dialysis is NOT effective for overdose
Probenecid blocks tubular secretion of uric acid and penicillin - used in gout; historically used to prolong penicillin effect
Amiodarone has an extremely long t½ (40-55 days) - interactions and toxicity may persist for months after stopping

Exam Emergency Facts (30-Second Rapid Review)

ADME = Absorption, Distribution, Metabolism, Excretion
Bioavailability of IV = 100%
Most absorption occurs in small intestine
First-pass = pre-systemic liver metabolism
Sublingual/IV/IM bypass first-pass
Vd = Dose / Cp₀; large Vd = drug in tissues
t½ = 0.693 × Vd / CL
Steady state reached in 4-5 t½
Loading dose based on Vd; maintenance dose based on CL
Inducer = reduces drug levels; Inhibitor = raises drug levels
Most potent inducer = Rifampicin
Most potent inhibitor = Ritonavir / Ketoconazole
Zero-order drugs: alcohol, phenytoin (at high doses), aspirin
Renal excretion = filtration + secretion - reabsorption
Only free drug is filtered at glomerulus, pharmacologically active
Phase I = CYP450; Phase II = conjugation (glucuronidation = most important)
M-6-G is more potent than morphine; accumulates in renal failure
Grey Baby Syndrome = chloramphenicol + immature glucuronidation in neonates

SECTION 12: SELF-ASSESSMENT

PART A: SBA/MCQs (20 Questions)

Q1. A drug has a bioavailability of 25% when given orally. The equivalent intravenous dose is 10 mg. What oral dose would produce the same plasma exposure?

A. 10 mg B. 25 mg C. 40 mg D. 100 mg

Answer: C - 40 mg Explanation: Bioavailability (F) = 0.25. Oral dose = IV dose / F = 10 / 0.25 = 40 mg. If only 25% reaches systemic circulation, you must give 4× the IV dose orally to achieve the same plasma exposure.

Q2. Which of the following correctly describes the Volume of Distribution?

A. The actual fluid volume in the body B. The volume of the vascular compartment C. The hypothetical volume in which the total drug dose would need to be dissolved to achieve the observed plasma concentration D. The volume of distribution is always equal to total body water

Answer: C Explanation: Vd is an apparent (hypothetical) volume. It can exceed total body water if the drug concentrates in tissues. Digoxin has a Vd of ~500 L in a 70 kg person whose total body water is only ~42 L.

Q3. Nitroglycerin is administered sublingually rather than orally because:

A. It is poorly absorbed from the gut B. It has low lipid solubility C. Sublingual administration bypasses first-pass hepatic metabolism D. The sublingual route provides slower, more sustained action

Answer: C Explanation: Nitroglycerin is rapidly and extensively metabolized by hepatic organic nitrate reductase. Oral bioavailability is <10-20%. Sublingual administration drains into the jugular vein, bypassing the portal circulation and liver, achieving therapeutic levels within minutes.

Q4. A patient is being treated with warfarin for atrial fibrillation. Rifampicin is added for tuberculosis. What is the expected outcome and why?

A. Increased anticoagulant effect - rifampicin inhibits warfarin metabolism B. Reduced anticoagulant effect - rifampicin induces CYP enzymes, increasing warfarin metabolism C. No change - rifampicin does not affect warfarin D. Increased anticoagulant effect - rifampicin displaces warfarin from plasma proteins

Answer: B Explanation: Rifampicin is the most potent clinical CYP enzyme inducer. It induces CYP2C9 (the enzyme primarily responsible for warfarin metabolism) and other CYP isozymes. This dramatically increases warfarin clearance, reducing plasma levels and anticoagulant effect. The INR will fall. The warfarin dose must be increased, and after stopping rifampicin, the dose must be reduced to avoid bleeding.

Q5. Which of the following statements about plasma protein binding is CORRECT?

A. Protein-bound drug can be filtered at the glomerulus B. Protein-bound drug is pharmacologically active C. Only the free (unbound) fraction of drug exerts pharmacological effects D. Protein binding increases the volume of distribution

Answer: C Explanation: Only free drug binds to receptors, crosses membranes, is filtered at the glomerulus, and exerts pharmacological effects. Protein-bound drug is a reservoir in plasma. Protein binding actually DECREASES Vd (keeps drug in plasma rather than distributing to tissues).

Q6. Which of the following drugs is eliminated by zero-order kinetics at therapeutic concentrations?

A. Penicillin B. Digoxin C. Phenytoin D. Gentamicin

Answer: C Explanation: Phenytoin saturates its hepatic hydroxylation enzymes even at therapeutic doses - meaning further dose increases lead to disproportionate rises in plasma levels. This makes phenytoin dosing difficult. At sub-therapeutic levels, it may follow first-order kinetics, but at therapeutic/supratherapeutic levels, zero-order (Michaelis-Menten saturation) kinetics apply. Alcohol is another classic zero-order example.

Q7. A drug has a half-life of 10 hours. Approximately how long will it take to reach steady state after starting regular dosing?

A. 10 hours B. 20 hours C. 40-50 hours D. 100 hours

Answer: C Explanation: Steady state is reached after 4-5 half-lives. With t½ = 10 hours, steady state is reached in 40-50 hours. This applies regardless of dose, dosing frequency, or route. The dose determines the LEVEL of steady state; dosing frequency determines the fluctuation between doses.

Q8. An overdose of aspirin (acetylsalicylic acid, a weak acid) is treated with sodium bicarbonate infusion. The mechanism of this treatment is:

A. Sodium bicarbonate chelates salicylate in the blood B. Alkalinizing the urine increases ionization of salicylate in the tubule, reducing reabsorption and increasing urinary excretion C. Sodium bicarbonate induces CYP enzymes to metabolize salicylate faster D. Sodium bicarbonate reduces GI absorption of remaining salicylate

Answer: B Explanation: This is ion trapping. Salicylate is a weak acid (pKa ~3). In alkaline urine, it remains ionized. Ionized drug cannot undergo passive reabsorption through the lipid tubular membrane. It stays in the tubular lumen and is excreted in urine. This principle: alkaline urine → increased excretion of weak acids.

Q9. Ketoconazole significantly increases the plasma concentration of simvastatin. The mechanism is:

A. Ketoconazole increases GI absorption of simvastatin B. Ketoconazole inhibits CYP3A4, reducing simvastatin metabolism C. Ketoconazole induces CYP3A4, increasing simvastatin production from a prodrug D. Ketoconazole displaces simvastatin from plasma proteins

Answer: B Explanation: Ketoconazole is a potent CYP3A4 inhibitor. Simvastatin is extensively metabolized by CYP3A4. When ketoconazole inhibits this enzyme, simvastatin plasma levels rise markedly, increasing the risk of myopathy and rhabdomyolysis. This combination should be avoided.

Q10. A patient develops grey baby syndrome after chloramphenicol treatment. The underlying pharmacokinetic mechanism is:

A. Excessive renal clearance of chloramphenicol in neonates B. Reduced protein binding leading to toxicity C. Immature uridine diphosphate glucuronosyltransferase (UGT) in neonates prevents glucuronidation of chloramphenicol, causing drug accumulation D. Increased GI absorption in neonates

Answer: C Explanation: Neonates have immature Phase II enzymes, especially UGT (UDP-glucuronosyltransferase). They cannot glucuronidate chloramphenicol effectively. The drug accumulates, causing cardiovascular collapse and grey cyanosis - grey baby syndrome. This illustrates the critical importance of developmental pharmacokinetics.

Q11. Which of the following drugs has the LARGEST volume of distribution?

A. Heparin B. Gentamicin C. Warfarin D. Chloroquine

Answer: D Explanation: Chloroquine has a Vd of ~200-800 L/kg due to extensive binding in melanin-containing tissues and other cellular compartments. For a 70 kg person, this represents tens of thousands of litres of apparent distribution. Heparin is a large molecule confined to plasma (small Vd ~0.06 L/kg). Gentamicin is polar and stays in ECF (~0.25 L/kg). Warfarin is highly protein-bound, keeping it in plasma (~0.1 L/kg).

Q12. Which statement BEST describes first-order drug elimination?

A. A constant amount of drug is eliminated per unit time B. Elimination rate is proportional to drug concentration C. Enzyme systems are fully saturated D. Clearance increases as plasma concentration increases

Answer: B Explanation: In first-order kinetics, the rate of elimination is proportional to the current drug concentration. A constant FRACTION (not amount) of the drug is eliminated per unit time. This produces an exponential decay curve and a constant half-life. Most drugs at therapeutic doses follow first-order kinetics.

Q13. A 75-year-old man with chronic kidney disease (GFR 20 mL/min) is prescribed digoxin. What pharmacokinetic change is MOST clinically relevant?

A. Increased Vd B. Decreased absorption C. Reduced renal clearance, leading to drug accumulation D. Increased protein binding

Answer: C Explanation: Digoxin is primarily excreted unchanged by the kidneys. Normal t½ ~36-40 hours. In severe CKD (GFR 20 mL/min = ~17% of normal), clearance falls proportionally and t½ can extend to over 5 days. Without dose adjustment, digoxin accumulates to toxic levels causing arrhythmias, nausea, visual disturbances.

Q14. The oral bioavailability of isosorbide mononitrate is approximately 100%, whereas isosorbide dinitrate has much lower bioavailability. The reason is:

A. Isosorbide mononitrate is more water-soluble B. Isosorbide mononitrate is not a substrate for organic nitrate reductase in the liver and therefore does not undergo significant first-pass metabolism C. Isosorbide mononitrate is better absorbed from the gut D. Isosorbide mononitrate binds more tightly to plasma proteins

Answer: B Explanation: Isosorbide mononitrate is an active metabolite of isosorbide dinitrate that has already had one nitrate group removed. It is not significantly metabolized by the hepatic organic nitrate reductase system during first-pass. Therefore, its oral bioavailability is ~100% and it is preferred for oral long-acting nitrate therapy.

Q15. You want to rapidly achieve a therapeutic plasma concentration of a drug with t½ = 36 hours. The MOST appropriate approach is to:

A. Give normal maintenance doses and wait 4-5 days B. Give a loading dose followed by regular maintenance doses C. Give the drug intravenously instead of orally D. Give twice the normal dose twice daily

Answer: B Explanation: With a long t½ (36 hours), steady state would not be achieved for 4-5 × 36 hours = 6-7.5 days. When rapid therapeutic effect is needed (e.g., digoxin in rapid atrial fibrillation), a loading dose is given to immediately achieve target plasma concentration. The loading dose is calculated from target Css × Vd. Maintenance doses then sustain this level.

Q16. Which of the following is NOT a route that bypasses hepatic first-pass metabolism?

A. Intravenous B. Sublingual C. Oral D. Transdermal

Answer: C Explanation: The oral route is the primary route that IS subject to first-pass metabolism. Drugs absorbed from the GI tract travel via the portal vein to the liver BEFORE reaching systemic circulation. IV, sublingual, and transdermal routes all deliver drugs directly to systemic circulation without passing through the liver first.

Q17. Which CYP enzyme metabolizes approximately 50% of all clinically used drugs?

A. CYP1A2 B. CYP2C9 C. CYP2D6 D. CYP3A4

Answer: D Explanation: CYP3A4 is the most abundant CYP enzyme in the liver (and also present in the gut wall) and metabolizes approximately 50% of all drugs. CYP2D6 metabolizes ~25% of drugs. CYP2C9 and CYP2C19 together metabolize a further 15-20%. CYP1A2 handles ~15%.

Q18. A patient taking oral morphine for cancer pain is switched to intravenous morphine. The oral:IV dose conversion ratio is approximately 3:1. The reason is:

A. IV morphine is less potent B. Oral morphine is destroyed by gastric acid C. Oral morphine undergoes significant first-pass hepatic metabolism, resulting in approximately 33% bioavailability D. IV morphine bypasses protein binding

Answer: C Explanation: Oral morphine has approximately 30-33% bioavailability due to extensive first-pass glucuronidation in the liver. To achieve the same plasma concentration, oral doses must be approximately 3× higher than IV doses. Clinicians must remember this when converting between routes to avoid under-dosing (inadequate analgesia) or over-dosing (respiratory depression).

Q19. Codeine is effective as an analgesic only in patients who have functional CYP2D6 enzyme. The pharmacokinetic reason is:

A. CYP2D6 is responsible for codeine absorption from the gut B. Codeine is a prodrug that requires CYP2D6-mediated O-demethylation to convert it to morphine, the active analgesic C. CYP2D6 prevents codeine from being excreted D. CYP2D6 converts codeine to a protein-bound form

Answer: B Explanation: Codeine itself has weak analgesic activity. It is converted to morphine by CYP2D6 (O-demethylation). Poor metabolizers (PM, lacking CYP2D6) receive no analgesic benefit. Ultra-rapid metabolizers (UM, with extra copies of CYP2D6) convert codeine too rapidly → morphine toxicity. Several infant deaths have been reported from breastfeeding mothers who were UMs taking codeine.

Q20. Why is dialysis ineffective for treating overdose with chloroquine or digoxin?

A. Both drugs are water-soluble B. Both drugs have extremely large volumes of distribution, meaning most drug is sequestered in tissues, not in plasma C. Both drugs are highly protein-bound and cannot be filtered D. Both drugs inhibit the dialysis membrane

Answer: B Explanation: Chloroquine (Vd ~200-800 L/kg) and digoxin (Vd ~500-700 L) have enormous volumes of distribution, meaning the vast majority of the total body drug is in tissues, not in the plasma being dialyzed. Dialysis only removes drug from plasma. With a huge Vd, removing even a significant fraction of the plasma drug concentration barely dents the total body load.

PART B: Clinical Case Questions (10 SAQs)

Case 1: A 55-year-old man with cirrhosis is prescribed oral diazepam 10 mg at night for insomnia. The following morning he is found deeply sedated and cannot be roused easily.

(a) What pharmacokinetic changes in cirrhosis explain this reaction? (b) What should have been done differently?

Model Answer:

(a) Cirrhosis causes multiple pharmacokinetic changes:

Reduced first-pass metabolism: Fewer functional hepatocytes → less CYP enzyme activity → higher oral bioavailability of diazepam than in a healthy person
Portosystemic shunting: Blood bypasses the liver entirely, further reducing first-pass effect
Reduced plasma albumin (hypoalbuminaemia): Liver produces albumin. In cirrhosis, albumin falls → reduced protein binding → higher free diazepam fraction → enhanced effect at standard dose
Reduced hepatic clearance: Diazepam is a low-extraction drug whose clearance depends on enzyme capacity, which is reduced in cirrhosis

Together, these changes result in higher plasma levels, higher free drug fraction, and prolonged half-life.

(b) Start with a much lower dose (e.g., 2-5 mg). Use short-acting benzodiazepines (e.g., temazepam) that undergo simple conjugation rather than CYP-dependent metabolism. Consider alternatives like a non-benzodiazepine. Monitor closely. Avoid benzodiazepines in severe hepatic encephalopathy.

Case 2: A patient on warfarin for prosthetic heart valve is started on rifampicin for tuberculosis. Three weeks later, her INR is 1.2 (target 2.5-3.5). She is shocked - "I'm taking my warfarin exactly as prescribed!"

(a) Explain the pharmacokinetic mechanism. (b) What are the clinical consequences and management?

Model Answer:

(a) Rifampicin is the most potent clinical inducer of CYP enzymes, including CYP2C9 (the primary enzyme metabolizing warfarin S-enantiomer) and CYP3A4. Rifampicin enters the hepatocyte, binds to the Pregnane X Receptor (PXR), and upregulates transcription of CYP genes. Over 1-2 weeks, CYP enzyme protein increases dramatically. Warfarin is now metabolized much faster → plasma levels fall → anticoagulant effect falls → INR drops.

(b) Consequences: Sub-therapeutic anticoagulation → risk of clot formation on prosthetic valve → stroke, embolism, valve thrombosis (potentially fatal).

Management: Significantly increase the warfarin dose (often 2-5x) with close INR monitoring while on rifampicin. Critically, when rifampicin is stopped, CYP induction reverses over weeks, warfarin levels will rise again - the dose must be reduced to avoid bleeding. This transition period requires very careful monitoring.

Case 3: A 70-year-old man is started on gentamicin for gram-negative sepsis. His serum creatinine is 250 μmol/L. On Day 3, he develops worsening kidney function and cannot hear properly on the right side.

(a) Explain why these complications occurred from a pharmacokinetic perspective. (b) How should aminoglycosides be dosed in elderly patients with renal impairment?

Model Answer:

(a) Gentamicin is a polar, water-soluble aminoglycoside eliminated almost entirely unchanged by glomerular filtration. At age 70, GFR is normally already reduced (by approximately 30% from the age-40 baseline). With a serum creatinine of 250 μmol/L, GFR is severely reduced (estimated by Cockcroft-Gault, perhaps 20-25 mL/min). Gentamicin clearance falls proportionally → t½ extends dramatically from 2 hours to 10-20+ hours → drug accumulates → nephrotoxicity (worsens renal function) and ototoxicity (cochlear damage → sensorineural hearing loss).

(b) In elderly patients with renal impairment: Calculate creatinine clearance (using Cockcroft-Gault). Extend the dosing interval (e.g., once-daily dosing instead of three times daily). Reduce dose if necessary. Monitor drug levels - trough levels must be very low (<1 mg/L for thrice-daily regimens) to avoid accumulation. Monitor renal function and hearing. Consider using a less nephrotoxic alternative if available.

Case 4: A 16-year-old girl takes her first oral contraceptive pill. She is also prescribed St. John's Wort (a herbal supplement) for mild depression by a naturopath. She becomes pregnant.

(a) Explain the mechanism of this drug interaction. (b) Which other medications face the same risk with St. John's Wort?

Model Answer:

(a) St. John's Wort (Hypericum perforatum) contains hyperforin, which is a potent inducer of CYP3A4 enzymes and P-glycoprotein. The combined oral contraceptive pill (OCP) contains ethinylestradiol and a progestogen, both metabolized by CYP3A4. Induction of CYP3A4 by St. John's Wort increases the metabolism of both hormones → plasma levels of ethinylestradiol and progestogen fall dramatically → inadequate blood levels to suppress ovulation → contraceptive failure. Additionally, P-glycoprotein induction may reduce intestinal absorption of the OCP.

(b) Other medications at risk: Warfarin (bleeding risk if St. John's Wort stopped), ciclosporin (organ rejection risk), HIV protease inhibitors (viral rebound), digoxin, carbamazepine, phenytoin. St. John's Wort should NEVER be used with these medications.

Case 5: Explain why insulin cannot be given orally, and what pharmacokinetic principles underlie this.

Model Answer:

Insulin is a polypeptide hormone (51 amino acids, MW ~5808 Da). When given orally:

Gastric acid (pH 1-2) partially denatures the protein structure
Proteolytic enzymes (pepsin in stomach, trypsin and chymotrypsin in small intestine) hydrolyze insulin into individual amino acids or small fragments - destroying its biological activity entirely
Even if intact insulin reached the gut wall, its large molecular size prevents passive diffusion across the lipid bilayer
Its low lipid solubility (it is hydrophilic) further impedes membrane crossing
Any fragment that did cross would undergo first-pass destruction in the liver

Therefore, insulin must be given parenterally - subcutaneously for long-term use, intravenously in emergencies. Researchers are working on inhaled, buccal, and nasal insulin delivery systems that bypass GI degradation and the first-pass effect.

Case 6: A patient is given a 500 mg intravenous loading dose of a drug. Immediately after injection, the plasma concentration is 10 mg/L. The drug's half-life is 8 hours.

(a) Calculate the Volume of Distribution. (b) Calculate the clearance. (c) How long until steady state is reached with regular dosing?

Model Answer:

(a) Volume of Distribution: Vd = Dose / Cp₀ = 500 mg / 10 mg/L = 50 litres

This is close to total body water (~42L), suggesting distribution mainly in body water, with some tissue penetration.

(b) Clearance: CL = 0.693 × Vd / t½ = 0.693 × 50 L / 8 h = 4.33 L/hour (or 72 mL/min)

(c) Time to Steady State: Steady state is reached in 4-5 × t½ = 4-5 × 8 hours = 32-40 hours

Case 7: A patient with severe pain is taking oral codeine but reports no analgesic effect at maximum doses. A pharmacogenetic test reveals she is a CYP2D6 poor metabolizer.

(a) Explain why codeine is ineffective in this patient. (b) What alternative would you recommend and why?

Model Answer:

(a) Codeine is a prodrug with intrinsically weak analgesic activity. Its analgesic effect primarily depends on conversion to morphine via CYP2D6-mediated O-demethylation in the liver. In poor metabolizers (approximately 7-10% of Caucasians, 1% of Asians), CYP2D6 is non-functional or absent. Very little codeine is converted to morphine. The patient experiences no analgesic benefit from codeine, regardless of dose.

(b) Alternatives: Opioids that do NOT require CYP2D6 activation:

Morphine (directly active - does not need conversion)
Oxycodone (partly converted by CYP2D6 to oxymorphone, but has direct activity too)
Tramadol (also requires CYP2D6, so should be avoided in PMs)
Fentanyl or buprenorphine (CYP3A4-metabolized, not CYP2D6-dependent)

Morphine would be the most appropriate step-up for moderate-severe cancer pain.

Case 8: A physician prescribes fluconazole for a fungal infection. The patient is also taking simvastatin 40 mg daily. Two days later the patient presents with severe muscle pain and dark urine (myoglobinuria).

(a) What is the pharmacokinetic explanation? (b) What is the clinical diagnosis, and how serious is this? (c) What should have been done to prevent this?

Model Answer:

(a) Simvastatin is a substrate of CYP3A4. Fluconazole is a potent inhibitor of CYP3A4 (and CYP2C9). When fluconazole inhibits CYP3A4, simvastatin metabolism is markedly reduced. Simvastatin plasma levels rise 10-30 fold. The dramatically elevated statin concentration is toxic to skeletal muscle cells.

(b) Clinical diagnosis: Rhabdomyolysis (breakdown of skeletal muscle → release of myoglobin → myoglobinuria → acute kidney injury). This is potentially life-threatening; severe cases cause acute renal failure and hyperkalemia.

(c) Prevention: Withhold simvastatin during fluconazole treatment (which is typically short-course). Use of pravastatin or rosuvastatin (not CYP3A4-dependent) would be safer alternatives if statin therapy must continue during azole treatment.

Case 9: Compare the plasma drug levels you would expect when giving the same drug: (a) As an IV bolus (b) As an oral tablet (c) As a slow-release transdermal patch

Using the concepts of absorption, first-pass, and bioavailability.

Model Answer:

(a) IV bolus:

Instantaneous entry into blood → immediate peak plasma concentration
100% bioavailability (F = 1)
Peak is sharp and high (Cmax)
Rapid initial distribution phase followed by elimination phase
Curve shows immediate peak followed by exponential decline

(b) Oral tablet:

Must dissolve, traverse GI tract, cross gut wall (absorb)
Portal vein → liver → first-pass metabolism reduces bioavailability (e.g., F = 0.3)
Gradual rise to Tmax (~1-2 hours), then gradual decline
Cmax is lower than IV; Tmax is delayed
AUC (oral) < AUC (IV) due to first-pass
Fluctuating blood levels with peaks and troughs

(c) Transdermal patch:

Drug released slowly from patch → absorbed through skin at controlled rate
Bypasses first-pass → potentially higher bioavailability than oral
Very slow rise to Cmax (many hours)
Sustained, relatively flat plasma concentration (minimal fluctuation)
Particularly useful for drugs with short half-lives requiring continuous plasma levels (e.g., fentanyl, nicotine, GTN)
Onset of action is very delayed

Case 10: A clinical pharmacist discovers that a patient has been prescribed both warfarin and amiodarone. She immediately alerts the physician that this is a potentially serious drug interaction.

(a) Explain the pharmacokinetic basis. (b) Explain why this interaction develops GRADUALLY. (c) What monitoring and management are required?

Model Answer:

(a) Amiodarone (and its active metabolite desethylamiodarone) are potent inhibitors of CYP2C9, the primary enzyme metabolizing the pharmacologically more active S-warfarin. Inhibition of CYP2C9 reduces warfarin clearance → warfarin plasma levels rise → anticoagulant effect increases dramatically → INR rises → bleeding risk.

(b) Unlike most enzyme inhibitors (which act rapidly), amiodarone's effect develops slowly for two reasons:

Amiodarone itself has an extremely long half-life (~40-55 days). It takes weeks to accumulate to steady state in the body where its inhibitory effect on CYP2C9 becomes maximal.
Reversing the interaction after stopping amiodarone also takes months, because the drug gradually leaves the body over many weeks.

(c) Management:

Immediately reduce warfarin dose by 30-50% when starting amiodarone
Monitor INR very frequently (every few days initially, then weekly)
Be prepared to continue reducing warfarin dose over the ensuing weeks as amiodarone accumulates
Continue INR monitoring for months AFTER stopping amiodarone (the interaction persists for weeks to months due to the very long t½ of amiodarone)
Educate the patient about signs of bleeding

Sources: Goodman & Gilman's The Pharmacological Basis of Therapeutics (13th Ed.); Katzung's Basic and Clinical Pharmacology (16th Ed.); Lippincott Illustrated Reviews: Pharmacology. All formulas and clinical examples verified against these texts.

---Your complete Pharmacokinetics learning note is above. Here is a quick summary of what it contains:

What You Just Received

This is a 12-section, textbook-replacing learning note on Pharmacokinetics, built directly from Goodman & Gilman, Katzung's Basic & Clinical Pharmacology, and Lippincott Illustrated Reviews: Pharmacology.

Sections at a Glance:

Section	Contents
Section 1	The Big Picture - What is PK, why it matters, ADME introduced
Section 2	Foundation Physiology - Cell membranes, fluid compartments, liver, kidney, GI tract, protein binding
Section 3	13 Core Concepts taught step-by-step: Absorption, Routes, Bioavailability, First-Pass, Distribution, Vd, Metabolism (Phase I/II), CYP450, Enzyme Induction/Inhibition, Excretion, Clearance, Half-life, Steady State, Loading/Maintenance Doses
Section 4	The Master Drug City Analogy - all concepts unified
Section 5	6 Step-by-Step Clinical Scenarios: IV vs oral, liver disease, renal failure, elderly, obesity
Section 6	The Pharmacokinetic Chain - how every concept connects to the next
Section 7	Flowcharts, ADME diagram, plasma-concentration curve, half-life graph, Phase I vs II comparison table
Section 8	Mnemonics (PC BRAS, SICKFACES, WAVED), Memory Story, Rapid Comparison Tables
Section 9	Examiner's Corner - top essays, SAQs, viva questions, MCQ traps, common misconceptions
Section 11	High-Yield Revision Sheet - all definitions, all formulas, clinical pearls, emergency facts
Section 12	20 SBAs/MCQs + 10 Clinical Case SAQs, all with detailed answers

This is a shared conversation. Sign in to Orris to start your own chat.